drugset / Trial / NCT03491579

Epacadostat, Cladribine and Cytarabine (ECC) in AML

NCT03491579

NaSingle-groupOpen-labelTreatment

Summary

This trial assess the maximum tolerated dose (MTD) and to characterize dose-limiting toxicities (DLTs) of epacadostat when added to the cladribine/cytarabine chemotherapy in relapsed / refractory AML patients fit for intensive treatment

Timeline

Start
2018-12
Primary completion
2019-09
Completion
2019-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Epacadostat Small molecule Oral
Background Cladribine Small molecule
Background Cytarabine Small molecule